> top > docs > PubMed:21784820 > annotations

PubMed:21784820 JSONTXT

Annnotations TAB JSON ListView MergeView

Inflammaging

Id Subject Object Predicate Lexical cue
T1 0-119 Sentence denotes Effect of phosphate binders on serum inflammatory profile, soluble CD14, and endotoxin levels in hemodialysis patients.
T2 120-146 Sentence denotes BACKGROUND AND OBJECTIVES:
T3 147-237 Sentence denotes Hyperphosphatemia and subclinical endotoxemia are important sources of inflammation in HD.
T4 238-383 Sentence denotes Proinflammatory cytokines are strong correlates of soluble CD14 (sCD14) concentrations, an independent predictor of mortality in this population.
T5 384-545 Sentence denotes We evaluated the effects of calcium acetate and sevelamer hydrochloride on serum inflammatory profile, endotoxin concentrations, and sCD14 levels in HD patients.
T6 546-592 Sentence denotes DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS:
T7 593-652 Sentence denotes Prospective, randomized, open-label, parallel design trial.
T8 653-756 Sentence denotes Fifty-nine stable HD patients, 30 receiving sevelamer, and 29 receiving calcium acetate were evaluated.
T9 757-993 Sentence denotes Serum levels of inflammatory parameters (high-sensitivity C-reactive protein [hs-CRP], TNF-α, interleukin (IL)-1, -6, -10, and -18), as well as endotoxin and sCD14 concentrations, were measured at baseline and after 3 months of therapy.
T10 994-1002 Sentence denotes RESULTS:
T11 1003-1203 Sentence denotes Serum IL-6 increased in patients receiving calcium acetate, whereas hs-CRP and IL-6 significantly decreased in subjects treated with sevelamer, with IL-10 experiencing a trend to increase (P = 0.052).
T12 1204-1289 Sentence denotes Serum endotoxin and sCD14 levels did not change after treatment with calcium acetate.
T13 1290-1403 Sentence denotes However, these parameters decreased by 22.6% and 15.2%, respectively (P < 0.01), in patients receiving sevelamer.
T14 1404-1687 Sentence denotes Multiple regression analysis showed that variation in serum endotoxin concentrations was the strongest factor associated with IL-6 change, whereas the only variables independently associated with changes in sCD14 levels were the variations in serum IL-6 and endotoxin concentrations.
T15 1688-1700 Sentence denotes CONCLUSIONS:
T16 1701-1895 Sentence denotes Administration of the noncalcium phosphate binder sevelamer to maintenance HD patients is associated with a significant decrease in hs-CRP, IL-6, serum endotoxin levels and sCD14 concentrations.
T1 0-119 Sentence denotes Effect of phosphate binders on serum inflammatory profile, soluble CD14, and endotoxin levels in hemodialysis patients.
T2 120-146 Sentence denotes BACKGROUND AND OBJECTIVES:
T3 147-237 Sentence denotes Hyperphosphatemia and subclinical endotoxemia are important sources of inflammation in HD.
T4 238-383 Sentence denotes Proinflammatory cytokines are strong correlates of soluble CD14 (sCD14) concentrations, an independent predictor of mortality in this population.
T5 384-545 Sentence denotes We evaluated the effects of calcium acetate and sevelamer hydrochloride on serum inflammatory profile, endotoxin concentrations, and sCD14 levels in HD patients.
T6 546-592 Sentence denotes DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS:
T7 593-652 Sentence denotes Prospective, randomized, open-label, parallel design trial.
T8 653-756 Sentence denotes Fifty-nine stable HD patients, 30 receiving sevelamer, and 29 receiving calcium acetate were evaluated.
T9 757-993 Sentence denotes Serum levels of inflammatory parameters (high-sensitivity C-reactive protein [hs-CRP], TNF-α, interleukin (IL)-1, -6, -10, and -18), as well as endotoxin and sCD14 concentrations, were measured at baseline and after 3 months of therapy.
T10 994-1002 Sentence denotes RESULTS:
T11 1003-1203 Sentence denotes Serum IL-6 increased in patients receiving calcium acetate, whereas hs-CRP and IL-6 significantly decreased in subjects treated with sevelamer, with IL-10 experiencing a trend to increase (P = 0.052).
T12 1204-1289 Sentence denotes Serum endotoxin and sCD14 levels did not change after treatment with calcium acetate.
T13 1290-1403 Sentence denotes However, these parameters decreased by 22.6% and 15.2%, respectively (P < 0.01), in patients receiving sevelamer.
T14 1404-1687 Sentence denotes Multiple regression analysis showed that variation in serum endotoxin concentrations was the strongest factor associated with IL-6 change, whereas the only variables independently associated with changes in sCD14 levels were the variations in serum IL-6 and endotoxin concentrations.
T15 1688-1700 Sentence denotes CONCLUSIONS:
T16 1701-1895 Sentence denotes Administration of the noncalcium phosphate binder sevelamer to maintenance HD patients is associated with a significant decrease in hs-CRP, IL-6, serum endotoxin levels and sCD14 concentrations.

PubmedHPO

Id Subject Object Predicate Lexical cue
T1 147-164 HP_0002905 denotes Hyperphosphatemia

Allie

Id Subject Object Predicate Lexical cue
SS1_21784820_3_0 289-301 expanded denotes soluble CD14
SS2_21784820_3_0 303-308 abbr denotes sCD14
SS1_21784820_8_0 798-833 expanded denotes high-sensitivity C-reactive protein
SS2_21784820_8_0 835-841 abbr denotes hs-CRP
SS1_21784820_8_1 851-862 expanded denotes interleukin
SS2_21784820_8_1 864-866 abbr denotes IL
AE1_21784820_3_0 SS1_21784820_3_0 SS2_21784820_3_0 abbreviatedTo soluble CD14,sCD14
AE1_21784820_8_0 SS1_21784820_8_0 SS2_21784820_8_0 abbreviatedTo high-sensitivity C-reactive protein,hs-CRP
AE1_21784820_8_1 SS1_21784820_8_1 SS2_21784820_8_1 abbreviatedTo interleukin,IL

Wangshuguang

Id Subject Object Predicate Lexical cue
T1 147-164 B-Variation denotes Hyperphosphatemia
T2 303-308 B-Variation denotes sCD14
T3 867-869 B-Variation denotes -1
T4 901-910 B-Variation denotes endotoxin
T5 1204-1209 I-Variation denotes Serum
T6 1210-1219 I-Variation denotes endotoxin
T7 1821-1829 B-Variation denotes decrease
T8 1847-1852 B-Variation denotes serum
T9 1853-1862 I-Variation denotes endotoxin
T10 1863-1869 I-Variation denotes levels

123123123

Id Subject Object Predicate Lexical cue
T1 147-164 B-Variation denotes Hyperphosphatemia
T2 303-308 B-Variation denotes sCD14
T3 867-869 B-Variation denotes -1
T4 901-910 B-Variation denotes endotoxin
T5 1204-1209 I-Variation denotes Serum
T6 1210-1219 I-Variation denotes endotoxin
T7 1821-1829 B-Variation denotes decrease
T8 1847-1852 B-Variation denotes serum
T9 1853-1862 I-Variation denotes endotoxin
T10 1863-1869 I-Variation denotes levels